drugset / Trial / NCT07690761
Rituximab+ Zanubrutinib for Patients With Hairy Cell Leukemia and Hairy Cell Variant
Phase 2
Enrolling by invitation
12 enrolled
Bnai Zion Medical Center
Hadassah Medical Organization · collabMeir Medical Center · collab
NaSingle-groupOpen-labelTreatment
Summary
investigators propose a phase II, open label-nonrandomized, single arm, multicenter study aiming to assess the safety and efficacy with the combination of Rituximab and Zanubrutinib in patients with HAIRY CELL LUKEMIA HCL, or HAIRY CELL LEUKEMIA VARIANT-HCLv.
Timeline
- Start
- 2026-06-01
- Primary completion
- 2028-12-31
- Completion
- 2033-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zanubrutinib | Small molecule | 160 mg | Oral |
| Subject | Zanubrutinib | Small molecule | 320 mg | Oral |